27 Results
Sort By:
Published on March 4, 2024
New data from the National Cancer Institute’s Molecular Analysis for Therapy Choice (NCI-MATCH) precision medicine clinical trial has shown in a Phase II study that the trastuzumab-pertuzumab combination therapy, already approved for the treatment of HER2-positive breast cancer, shrunk the tumors of several other cancer types. The findings warrant additional…
Published on May 25, 2022
A landmark study in people with breast cancer has shown that the oral antidiabetic agent metformin does not delay disease recurrence or death overall but may be effective in a subgroup of people with human epidermal growth factor receptor (HER)2-positive tumors. The phase 3 MA.32 trial, led by Pamela Goodwin…
Published on April 7, 2020
New research from Peru shows a link between a greater incidence of HER2-positive breast cancer in women with Indigenous American (IA) ancestry, suggesting the presence of a population-specific genetic variant. Researchers with the Peruvian Genetics and Genomics of Breast Cancer study (PEGEN-BC) reported on genome-wide data from 1,312 patients who…
Published on December 6, 2023
Patients with node-positive breast cancer that becomes node-negative after neoadjuvant chemotherapy can omit regional nodal irradiation (RNI) without increasing their risk for recurrence, suggests data presented at the 2023 San Antonio Breast Cancer Symposium. The de-escalation of treatment could spare a large proportion of patients the side effects associated with…
Published on November 27, 2023
A groundbreaking study conducted at Northwestern Medicine suggests that an artificial intelligence (AI) tool could spare breast cancer patients unnecessary chemotherapy treatments by more accurately predicting patient outcomes. The research, published today in Nature Medicine, shows that the AI tool outperformed the analysis of disease by expert pathologists. While current…
Published on May 19, 2023
Researchers at Baylor College of Medicine and collaborators have developed and validated a multiparameter molecular classifier test that allows scientists to predict which HER2-positive breast cancer patients could be spared from chemotherapy by receiving anti-HER2 treatment only. About one in every five breast cancer patients is HER2-positive—meaning that the cancer…
Published on October 17, 2022
Researchers at the Hospital del Mar medical research institute (IMIM) in Barcelona, Spain have discovered how to overcome a treatment resistance mechanism in one of the most aggressive types of breast cancer by activating the body’s immune response. HER2 positive breast cancer tends to grow faster, spread and recur more…
Published on August 8, 2022
On Friday, the U.S. Food and Drug Administration (FDA) approved trastuzumab-deruxtecan—sold under the brand name Enhertu—for the treatment of patients with unresectable or metastatic HER2-low breast cancer. Administered through IV infusion, the drug is the first approved therapy for patients with the newly identified HER2-low breast cancer subtype. The expanded…
Published on June 6, 2022
AstraZeneca has established that targeting HER-2 low breast cancer works, and very well, by presenting striking Phase III results at the American Society of Clinical Oncology (ASCO) this week. Enhertu (trastuzumab deruxtecan) demonstrated a 49% reduction in the risk of disease progression or death versus chemotherapy in patients with HER2-low metastatic breast…
Published on September 21, 2021
Over the last week, the world of cancer research, diagnostics and therapeutics has been congregating on the European Society of Medical Oncology (ESMO) website to view a wide variety of cutting-edge research presentations at the organization’s annual conference. The biggest congress in Europe with a focus on cancer research, the…
Published on February 1, 2021
Finnish investigators have recently identified a protein trafficking receptor, usually studied in neurons, that plays a key role in breast cancer metastasis. The scientists at the University of Turku Bioscience Center observed that the Sortilin-related receptor (SorLA) functionally contributes to the most reported therapy-resistant mechanism by which the cell-surface receptor…
Published on January 8, 2020
Scientists at the University of Chicago have discovered a new class of drug compounds to potentially treat FOXM1positive breast cancer. This would be the first known type of drug to treat the FOXM1 mutation, and the new compounds have been shown to suppress tumor growth in preclinical breast tumor models, though…
Published on February 25, 2019
New personalized diagnostic and prognostic approaches offer novel strategies to spare some cancer patients unnecessarily harsh and toxic treatments. Most recently, a study published in the Journal of Clinical Oncology in February reports that PET scans can predict which breast cancer patients will respond successfully to targeted HER2- immunotherapy treatments,…
Published on February 7, 2019
New research out of the Scripps Research Institute is showing early promise in being able to address treatment for a form of cancer which, to date, has no targeted therapies—HER2-negative breast cancer. The study, published in the Journal of the American Chemical Society, from the research lab of Matthew D.…
Published on May 7, 2018
One in eight women will be diagnosed with breast cancer in her lifetime, and one in 30 is expected to die from it. Thus, understanding the underlying molecular mechanisms that cause breast tumors to become metastatic is critical for improved therapies and patient outcomes. Now, investigators at the Montreal Clinical…